Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Astonea Labs
Quarter-by-quarter operating performance
Financials of Astonea Labs
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Sales + | 30.04 | 66.89 | 80.06 | 97.38 |
| Expenses + | 24.21 | 59.75 | 68.14 | 82.09 |
| Operating Profit | 5.83 | 7.14 | 11.92 | 15.29 |
| OPM % | 19.41% | 10.67% | 14.89% | 15.70% |
| Other Income + | 0.12 | 0.21 | 0.10 | 0.19 |
| Interest | 1.58 | 2.34 | 2.97 | 3.83 |
| Depreciation | 3.79 | 3.93 | 3.67 | 4.58 |
| Profit before tax | 0.58 | 1.08 | 5.38 | 7.07 |
| Tax % | 56.90% | 38.89% | 24.35% | 24.33% |
| Net Profit + | 0.25 | 0.67 | 4.07 | 5.35 |
| EPS in Rs | 0.62 | 1.68 | 5.36 | 6.93 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Astonea Labs
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 4.00 | 4.00 | 7.60 | 7.72 | 10.51 |
| Reserves | 3.49 | 4.16 | 4.26 | 10.69 | 42.96 |
| Borrowings + | 29.53 | 35.99 | 42.39 | 53.33 | 39.05 |
| Other Liabilities + | 15.89 | 20.13 | 26.47 | 31.64 | 29.30 |
| Total Liabilities | 52.91 | 64.28 | 80.72 | 103.38 | 121.82 |
| Fixed Assets + | 21.39 | 20.75 | 21.75 | 25.03 | 26.08 |
| CWIP | 0.00 | 0.00 | 2.10 | 5.01 | 6.27 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets + | 31.52 | 43.53 | 56.87 | 73.34 | 89.47 |
| Total Assets | 52.91 | 64.28 | 80.72 | 103.38 | 121.82 |
Financials of Astonea Labs
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -4.93 | -1.05 | 7.86 | 9.25 |
| Cash from Investing Activity + | -3.31 | -3.08 | -8.35 | -11.14 |
| Cash from Financing Activity + | 8.17 | 4.14 | -0.26 | 1.62 |
| Net Cash Flow | -0.07 | 0.01 | -0.75 | -0.27 |
| Free Cash Flow | -8.26 | -4.17 | 0.42 | -1.51 |
| CFO/OP | -75% | -9% | 71% | 70% |
Financials of Astonea Labs
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 234.63 | 104.11 | 115.94 | 141.91 |
| Inventory Days | 136.35 | 121.40 | 160.81 | 160.68 |
| Days Payable | 273.08 | 128.11 | 148.90 | 143.66 |
| Cash Conversion Cycle | 97.89 | 97.41 | 127.85 | 158.93 |
| Working Capital Days | 98.30 | 32.79 | 28.22 | 29.31 |
| ROCE % | 8.01% | 16.97% | 17.30% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…